Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - 04/11/20

Doi : 10.1016/S1470-2045(20)30441-1

Franck Morschhauser, ProfMD ^a,⁎ , Hervé Tilly, MD ^b, Aristeidis Chaidos, MD ^c, Pamela McKay, MD ^d, Tycel Phillips, MD ^e, Sarit Assouline, MD ^f,^g, Connie Lee Batlevi, MD ^h, Phillip Campbell, MD ⁱ, Vincent Ribrag, MD ^j, Gandhi Laurent Damaj, ProfMD ^k, Michael Dickinson, MD ^l,^m, Wojciech Jurczak, ProfMD ⁿ, Maciej Kazmierczak, MD ^o, Stephen Opat, ProfMD ^p, John Radford, ProfMD ^q,^r, Anna Schmitt, MD ^s, Jay Yang, PhD ^t, Jennifer Whalen, DHS ^t, Shefali Agarwal, MBBS ^t, Deyaa Adib, MD ^t, Gilles Salles, ProfMD ^u

^a Groupe de Recherche sur les formes Injectables et les Technologies Associées, CHU de Lille, Université de Lille, Lille, France

^b Department of Hematology and INSERM U1245, Centre Henri Becquerel and Rouen University, Rouen, France

^c Centre for Haematology, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, Hammersmith Hospital & Imperial College Healthcare NHS Trust, London, UK

^d Department of Hematology, Beatson West of Scotland Cancer Centre, Glasgow, UK

^e Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA

^f Division of Hematology, Jewish General Hospital, Montreal, QC, Canada

^g Department of Oncology, McGill University, Montreal, QC, Canada

^h Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

ⁱ Department of Clinical Haematology, Barwon Health, University Hospital Geelong, Geelong, VIC, Australia

^j Hematology Department, Gustave Roussy, Villejuif, France

^k Hematology Institute, Hematologie Clinique, University Hospital School of Medicine, Caen, France

^l Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, VIC, Australia

^m Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia

ⁿ Department of Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland

^o Department of Hematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland

^p Haematology Department, Monash University, Melbourne, VIC, Australia

^q Department of Medical Oncology, University of Manchester, Manchester, UK

^r NIHR Manchester Clinical Research Facility, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Manchester, UK

^s Department of Hematology, Institut Bergonié, Bordeaux, France

^t Clinical Development, Epizyme, Cambridge, MA, USA

^u Department of Hematology, Lyon-Sud Hospital, University of Lyon, Pierre-Bénite, France

^* Correspondence to: Prof Franck Morschhauser, Groupe de Recherche sur les formes Injectables et les Technologies Associées, CHU de Lille, Université de Lille, Lille F-59000, France Groupe de Recherche sur les formes Injectables et les Technologies Associées CHU de Lille Université de Lille Lille F-59000 France

Summary

Background

Activating mutations of EZH2, an epigenetic regulator, are present in approximately 20% of patients with follicular lymphoma. We investigated the activity and safety of tazemetostat, a first-in-class, oral EZH2 inhibitor, in patients with follicular lymphoma.

Methods

This study was an open-label, single-arm, phase 2 trial done at 38 clinics or hospitals in France, the UK, Australia, Canada, Poland, Italy, Ukraine, Germany, and the USA. Eligible patients were adults (≥18 years) with histologically confirmed follicular lymphoma (grade 1, 2, 3a, or 3b) that had relapsed or was refractory to two or more systemic therapies, had an Eastern Cooperative Oncology Group performance status of 0–2, and had sufficient tumour tissue for central testing of EZH2 mutation status. Patients were categorised by EZH2 status: mutant (EZH2^mut) or wild-type (EZH2^WT). Patients received 800 mg of tazemetostat orally twice per day in continuous 28-day cycles. The primary endpoint was objective response rate based on the 2007 International Working Group criteria for non-Hodgkin lymphoma, assessed by an independent radiology committee. Activity and safety analyses were done in patients who received one dose or more of tazemetostat. This study is registered with ClinicalTrials.gov, NCT01897571, and follow-up is ongoing.

Findings

Between July 9, 2015, and May 24, 2019, 99 patients (45 in the EZH2^mut cohort and 54 in the EZH2^WT cohort) were enrolled in the study. At data cutoff for the analysis (Aug 9, 2019), the median follow-up was 22·0 months (IQR 12·0–26·7) for the EZH2^mut cohort and 35·9 months (24·9–40·5) for the EZH2^WT cohort. The objective response rate was 69% (95% CI 53–82; 31 of 45 patients) in the EZH2^mut cohort and 35% (23–49; 19 of 54 patients) in the EZH2^{WT cohort.} Median duration of response was 10·9 months (95% CI 7·2–not estimable [NE]) in the EZH2^mut cohort and 13·0 months (5·6–NE) in the EZH2^WT cohort; median progression-free survival was 13·8 months (10·7–22·0) and 11·1 months (3·7–14·6). Among all 99 patients, treatment-related grade 3 or worse adverse events included thrombocytopenia (three [3%]), neutropenia (three [3%]), and anaemia (two [2%]). Serious treatment-related adverse events were reported in four (4%) of 99 patients. There were no treatment-related deaths.

Interpretation

Tazemetostat monotherapy showed clinically meaningful, durable responses and was generally well tolerated in heavily pretreated patients with relapsed or refractory follicular lymphoma. Tazemetostat is a novel treatment for patients with follicular lymphoma.

Funding

Epizyme.

Le texte complet de cet article est disponible en PDF.

Plan

Introduction

Methods

Study design and participants

Procedures

Outcomes

Statistical analysis

Role of the funding source

Results

Discussion

Data sharing

Export

Vol 21 - N° 11

P. 1433-1442 - novembre 2020 Retour au numéro

Article précédent

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Mrinal Gounder, Patrick Schöffski, Robin L Jones, Mark Agulnik, Gregory M Cote, Victor M Villalobos, Steven Attia, Rashmi Chugh, Tom Wei-Wu Chen, Thierry Jahan, Elizabeth T Loggers, Abha Gupta, Antoine Italiano, George D Demetri, Ravin Ratan, Lara E Davis, Olivier Mir, Palma Dileo, Brian A Van Tine, Joseph G Pressey, Trupti Lingaraj, Anand Rajarethinam, Laura Sierra, Shefali Agarwal, Silvia Stacchiotti

| Article suivant

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial
Ian Smith, John Robertson, Lucy Kilburn, Maggie Wilcox, Abigail Evans, Chris Holcombe, Kieran Horgan, Cliona Kirwan, Elizabeth Mallon, Mark Sibbering, Anthony Skene, Raghavan Vidya, Maggie Cheang, Jane Banerji, James Morden, Kally Sidhu, Andrew Dodson, Judith M Bliss, Mitch Dowsett

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - 04/11/20

Summary

Background

Methods

Findings

Interpretation

Funding

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL